PARTNERSHIP OPPORTUNITIES
Connect with Decision Makers in Obesity
The 2nd Innovation in Obesity Therapeutics Summit offers an unparalleled platform to connect directly with 60+ senior leaders and pioneering drug development experts driving innovation in obesity therapeutics. This is your exclusive opportunity to:
- Position your company at the forefront of this rapidly evolving and highly impactful field, and forge strategic partnerships that will accelerate your growth and impact in tackling metabolic disease
- Connect with a highly targeted audience of decision-makers dedicated to the intricacies of obesity pathogenesis, from foundational biology to advanced clinical applications
This summit creates the ideal environment to cultivate meaningful collaborations and explore synergistic opportunities with leading companies. Join us to network with influential voices from top biopharma companies including Eli Lilly, Boehringer Ingelheim, Supercede Therapeutics and Veru and unlock the potential for transformative partnerships that will shape the future of obesity medicines.
Current Partners
Key Interest Areas:
Preclinical CROs alongside expertise in preclinical modeling and obesity research to provide advanced in vitro and in vivo animal and muscle models to accurately replicate human disease progression. This helps in validating novel targets, establishing mechanisms of action, and providing predictive insights into therapeutic response for new drug candidates
Biomarkers - including novel, validated for obesity and metabolic disease to be used as endpoints in clinical trials, and assessing treatment response
Clinical CROs with deep expertise in obesity clinical trial design and specializing in patient recruitment, efficient study execution, and patient retention strategies for long-term outcome studies
Clinical Services designed to enhance the clinical development process. This includes patient-centric trial design, support for decentralized clinical trials, and the integration of digital health and wearable technology to improve patient engagement and data collection. These services aim to streamline the clinical pathway and ensure robust, patient-friendly outcomes
Attending Companies Include:
Why Partner?
Showcase your solutions in preclinical modeling, biomarkers, or CRO capabilities, with the advantage of allowing you to position your company as a thought leader and secure new business from an audience of 60+ senior scientists and clinical development leaders
Elevate your brand presence within a highly targeted and influential obesity drug development community, with the advantage of building lasting recognition and credibility among key decision-makers, thereby helping you secure a competitive advantage
Forge strategic collaborations with 60+ obesity drug developers from expert biotechs and pharmaceutical giants, providing an exclusive opportunity to engage in direct, high-level discussions
Gain access to a platform connecting the entire drug development ecosystem, from early stage biology to clinical application, giving you a holistic view of the market and helping you refine your business strategy by staying informed on the most recent advancements and emerging trends
Get In Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
Molly Biggin
Partnerships Director